{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:52:34Z","timestamp":1767682354511,"version":"3.48.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,5]]},"DOI":"10.7759\/cureus.100880","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:49:13Z","timestamp":1767682153000},"source":"Crossref","is-referenced-by-count":0,"title":["The Successful Treatment of Primary and Recurrent Ruptured Gastric Gastrointestinal Stromal Tumor (GIST) Through Coordinated Surgical Intervention and c-Kit Inhibitor Therapy"],"prefix":"10.7759","author":[{"given":"Shintaro","family":"Hirayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujo","family":"Kawashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Haraguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouya","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sousei","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Washida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Hachitanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2015.10.031","article-title":"Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies","volume":"40","author":"S\u00f8reide K","year":"2016","unstructured":"S\u00f8reide K, Sandvik OM, S\u00f8reide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016, 40:39-46. 10.1016\/j.canep.2015.10.031","journal-title":"Cancer Epidemiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc314","article-title":"Gastrointestinal stromal tumours: origin and molecular oncology","volume":"11","author":"Corless CL","year":"2011","unstructured":"Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011, 11:865-78. 10.1038\/nrc314","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60106-3","article-title":"Gastrointestinal stromal tumour","volume":"382","author":"Joensuu H","year":"2013","unstructured":"Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013, 382:973-83. 10.1016\/S0140-6736(13)60106-3","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri GD","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, et al.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002, 347:472-80. 10.1056\/NEJMoa020461","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10104","article-title":"Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine","volume":"103","author":"H\u00f8lmebakk T","year":"2016","unstructured":"H\u00f8lmebakk T, Bjerkehagen B, Boye K, Bruland \u00d8, Stoldt S, Sundby Hall K. Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine. Br J Surg. 2016, 103:684-91. 10.1002\/bjs.10104","journal-title":"Br J Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6505-7","article-title":"Clinicopathological features and prognosis of primary GISTs with tumor rupture in the real world","volume":"25","author":"Nishida T","year":"2018","unstructured":"Nishida T, Cho H, Hirota S, Masuzawa T, Chiguchi G, Tsujinaka T. Clinicopathological features and prognosis of primary GISTs with tumor rupture in the real world. Ann Surg Oncol. 2018, 25:1961-9. 10.1245\/s10434-018-6505-7","journal-title":"Ann Surg Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.005","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Casali PG","year":"2022","unstructured":"Casali PG, Blay JY, Abecassis N, et al.. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:20-33. 10.1016\/j.annonc.2021.09.005","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02738-z","article-title":"Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial","volume":"131","author":"Joensuu H","year":"2024","unstructured":"Joensuu H, Reichardt A, Eriksson M, et al.. Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial. Br J Cancer. 2024, 131:299-304. 10.1038\/s41416-024-02738-z","journal-title":"Br J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70299-6","article-title":"Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts","volume":"13","author":"Joensuu H","year":"2012","unstructured":"Joensuu H, Vehtari A, Riihimaki J, et al.. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012, 13:265-274. 10.1016\/S1470-2045(11)70299-6","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07297-9","article-title":"Defining tumor rupture in gastrointestinal stromal tumor","volume":"26","author":"Nishida T","year":"2019","unstructured":"Nishida T, H\u00f8lmebakk T, Raut CP, Rutkowski P. Defining tumor rupture in gastrointestinal stromal tumor. Ann Surg Oncol. 2019, 26:1669-75. 10.1245\/s10434-019-07297-9","journal-title":"Ann Surg Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich MC","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, et al.. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003, 21:4342-9. 10.1200\/JCO.2003.04.190","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3980","article-title":"KIT and PDGFRA mutations and survival of gastrointestinal stromal tumor patients treated with adjuvant imatinib in a randomized trial","volume":"29","author":"Joensuu H","year":"2023","unstructured":"Joensuu H, Wardelmann E, Eriksson M, et al.. KIT and PDGFRA mutations and survival of gastrointestinal stromal tumor patients treated with adjuvant imatinib in a randomized trial. Clin Cancer Res. 2023, 29:3313-9. 10.1158\/1078-0432.CCR-22-3980","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"Joensuu H","year":"2012","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, et al.. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012, 307:1265-72. 10.1001\/jama.2012.347","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.9170","article-title":"Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial","volume":"34","author":"Joensuu H","year":"2016","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, et al.. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol. 2016, 34:244-50. 10.1200\/JCO.2015.62.9170","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2343","article-title":"A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse","volume":"35","author":"Blay JY","year":"2024","unstructured":"Blay JY, Schiffler C, Bouch\u00e9 O, et al.. A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. Ann Oncol. 2024, 35:1157-68. 10.1016\/j.annonc.2024.08.2343","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3866-4","article-title":"The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses","volume":"21","author":"Park SJ","year":"2014","unstructured":"Park SJ, Ryu MH, Ryoo BY, et al.. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Ann Surg Oncol. 2014, 21:4211-7. 10.1245\/s10434-014-3866-4","journal-title":"Ann Surg Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2605.2007.00755.x","article-title":"Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat","volume":"30","author":"Nurmio M","year":"2007","unstructured":"Nurmio M, Toppari J, Zaman F, Andersson AM, Paranko J, S\u00f6der O, Jahnukainen K. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl. 2007, 30:366-76. 10.1111\/j.1365-2605.2007.00755.x","journal-title":"Int J Androl"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-017-0521-6","article-title":"Impact of imatinib on the fertility of male patients with chronic myelogenous leukaemia in the chronic phase","volume":"12","author":"Chang X","year":"2017","unstructured":"Chang X, Zhou L, Chen X, et al.. Impact of imatinib on the fertility of male patients with chronic myelogenous leukaemia in the chronic phase. Target Oncol. 2017, 12:827-32. 10.1007\/s11523-017-0521-6","journal-title":"Target Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2010.12.056","article-title":"Imatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal","volume":"31","author":"Heim C","year":"2011","unstructured":"Heim C, Minniear K, Dann CT. Imatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal. Reprod Toxicol. 2011, 31:454-63. 10.1016\/j.reprotox.2010.12.056","journal-title":"Reprod Toxicol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.33407","article-title":"The impact of tyrosine kinase inhibitors on fatherhood in patients with chronic myeloid leukemia: a mixed-method study","volume":"15","author":"Abu-Tineh M","year":"2023","unstructured":"Abu-Tineh M, Ali EA, Alshurafa A, et al.. The impact of tyrosine kinase inhibitors on fatherhood in patients with chronic myeloid leukemia: a mixed-method study. Cureus. 2023, 15:e33407. 10.7759\/cureus.33407","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/360723-the-successful-treatment-of-primary-and-recurrent-ruptured-gastric-gastrointestinal-stromal-tumor-gist-through-coordinated-surgical-intervention-and-c-kit-inhibitor-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:49:14Z","timestamp":1767682154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/360723-the-successful-treatment-of-primary-and-recurrent-ruptured-gastric-gastrointestinal-stromal-tumor-gist-through-coordinated-surgical-intervention-and-c-kit-inhibitor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.100880","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}